Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this phase II study is to evaluate an investigational monoclonal antibody for
the treatment of glucocorticoid-refractory Graft Versus Host Disease (GVHD). Patients
diagnosed with GVHD who have not responded satisfactorily to, or are intolerant of, treatment
with standard agents will be considered for entry. Patients will be allowed to continue on
their other immunosuppressive drugs at stable doses during the trial. The research is being
conducted at up to 20 clinical research sites in the US.